Karen L. Smith
CIK: 0001639637
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 24, 2026CNTX
Context Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - Mar 31, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
75K shares- - Feb 6, 2026SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
35K shares- - Jun 12, 2025SGMO
SANGAMO THERAPEUTICS, INC
Award(A)Direct25K shares- - Jun 12, 2025CNTX
Context Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
123.5K shares- - Feb 24, 2025SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
35K shares- - Nov 21, 2024AUPH
Aurinia Pharmaceuticals Inc.
Award(A)Direct12.1K shares- - Nov 11, 2024AUPH
Aurinia Pharmaceuticals Inc.
Sale(S)Direct5.2K shares at avg. $8.43$44K - Nov 8, 2024AUPH
Aurinia Pharmaceuticals Inc.
Exercise(M)Direct17.9K shares- - Oct 28, 2024SKYE
Skye Bioscience, Inc.
Award(A)DirectStock Option (Right to Buy)
70K shares- - Sep 4, 2024CNTX
Context Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
19.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 |  CNTX Context Therapeutics Inc. | Award(A) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Mar 31, 2026 |  SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 75,000 | - | - | Direct |
| Feb 6, 2026 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 35,000 | - | - | Direct |
| Jun 12, 2025 |  SGMO SANGAMO THERAPEUTICS, INC | Award(A) | 25,000 | - | - | Direct |
| Jun 12, 2025 | CNTX Context Therapeutics Inc. | Award(A) Stock Option (right to buy) | 123,500 | - | - | Direct |
| Feb 24, 2025 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 35,000 | - | - | Direct |
| Nov 21, 2024 |  AUPH Aurinia Pharmaceuticals Inc. | Award(A) | 12,135 | - | $0 | Direct |
| Nov 11, 2024 | AUPH Aurinia Pharmaceuticals Inc. | Sale(S) | 5,241 | $8.43 | $44,182 | Direct |
| Nov 8, 2024 | AUPH Aurinia Pharmaceuticals Inc. | Exercise(M) | 17,913 | - | $0 | Direct |
| Oct 28, 2024 | SKYE Skye Bioscience, Inc. | Award(A) Stock Option (Right to Buy) | 70,000 | - | - | Direct |
| Sep 4, 2024 | CNTX Context Therapeutics Inc. | Award(A) Stock Option (right to buy) | 19,315 | - | - | Direct |
1-11 of 11 transactions
About Smith Karen L.
Smith Karen L. (SEC CIK 0001639637) files insider reports with the SEC as Director of Context Therapeutics Inc. (CNTX), Director of Skye Bioscience, Inc. (SKYE) and Director of SANGAMO THERAPEUTICS, INC (SGMO). Signal8 also holds filings tied to 1 other company.
Signal8 holds 11 ownership filings by Smith Karen L. (1 Form 3, 10 Form 4), filed between Sep 5, 2024 and Jun 26, 2026. Those filings report 11 transactions, from Sep 4, 2024 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith Karen L.'s filings is in PHILADELPHIA, PA.
Recent filings by Smith Karen L.
- Jun 24, 2026: Grant or award of CNTX derivative securities (Form 4, code A).
- Mar 31, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
- Feb 6, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
- Jun 12, 2025: Grant or award of SGMO shares (Form 4, code A).
- Jun 12, 2025: Grant or award of CNTX derivative securities (Form 4, code A).
Other insiders filing for Context Therapeutics Inc. (CNTX)
- Pasternak Andy, Director
- Stacey Jennifer Evans, Director
- West Linda, Director
- Walker Luke Nathaniel, Director
- Kantoff Philip W., Director
- Levit Alex C., Chief Legal Officer, Corp. Sec